New $35 million partnership to advance blood disorder therapies

20 May 2025

A new frontier into advancing treatments for children and adults with bone marrow failure, leukemia and other blood disorders will be achieved under a new partnership between Murdoch Children’s Research Institute (MCRI) and US biotech Retro Biosciences.

MCRI, a flagship member of the Melbourne Biomedical Precinct and the Melbourne arm of the international research consortium, the Novo Nordisk Foundation Center for Stem Cell Medicines (reNEW) has announced a significant research and commercial licensing agreement with Retro Biosciences. The agreement will advance a blood stem cell breakthrough, discovered by MCRI scientists last year, that could pave the way for new therapies for patients around the world.

The partnership, worth over $35 million, will further develop MCRI’s field-leading research and technology by licensing the blood stem cell discovery IP to Retro Biosciences for the development of new, personalised therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK